



BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences

May 15, 2019

LAVAL, Quebec--(BUSINESS WIRE)-- BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at three upcoming healthcare investor conferences.

Conference Presentation Details:

Event: UBS 2019 Global Healthcare Conference

Date/Time: Monday, May 20, 2019 at 3:30 p.m. EDT

Location: New York, NY

Event: Jefferies 2019 Healthcare Conference

Date/Time: Wednesday, June 5, 2019 at 3:30 p.m. EDT

Location: New York, NY

Event: Raymond James Life Sciences and MedTech Conference

Date/Time: Wednesday, June 19, 2019 at 8:35 a.m. EDT

Location: New York, NY

Live webcasts from the UBS, Jefferies and Raymond James conference presentations may be accessed on the [Events and Presentations](#) page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the events, archived webcasts and presentations will be available on the Company's website.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's lead product candidate, BLU-5937, is being developed for the treatment of chronic cough. BLU-5937, a highly selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. In addition to chronic cough, BLU-5937 may potentially have clinical benefit in other afferent hypersensitization-related disorders, such as visceral pain, hypertension, and migraine, among others. BELLUS Health is currently conducting pre-clinical studies in additional undisclosed indications.

Chronic cough is classified as a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality-of-life. More than 26 million adults in the United States suffer from chronic cough. Of these patients, more than 2.6 million have unexplained or refractory chronic cough lasting for more than a year. There are currently no approved treatments for refractory chronic cough, creating a significant unmet medical need.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

BELLUS Health
François Desjardins

Vice-President, Finance
450-680-4525
fdesjardins@bellushealth.com

Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com

Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@soleburytrout.com

Source: BELLUS Health Inc.